VRNA - Rasio rega marang pendapatan Verona Pharma PLC
Verona Pharma plc (VRNA) is commercializing advanced COPD treatments, anticipating high margins and stable cash flow. Patent protection and a unique therapeutic method enable the company to maintain pricing power for its treatments. The business is currently establishing a distribution network for a large-scale product launch. The median P/S captures the price-to-sales valuation trend, where the 41.30 level indicates the status of the parameter.
Rincian metrik lan analitis perusahaan Verona Pharma Corp (VRNA)
- rega saham lan konsensus proyeksi valuasi:
- statistik kapitalisasi pasar:
- statistik nilai buku emiten:
- statistik kawajiban utang lan likuiditas:
Utang marang Modal Verona Pharma plc|VRNA - Utang jangka dawa marang ekuitas|Rasio utang jangka cendhak marang modal Verona Pharma Inc.|VRNA - Gunggung utang perusahaan|Utang-utang marang kapitalisasi buku Verona Pharma Corp|VRNA - Kewajiban jangka dawa perusahaan|Silihan lan utang jangka cendhak perusahaan Verona Pharma|Rasio likuiditas kritis veronapharma.com
- data bathi lan kelipatan valuasi:
VRNA - Bathi resik|Penghasilan resik sing dikarepake Verona Pharma plc|VRNA - Pangali P/E|Pangali Forward P/E Verona Pharma PLC|VRNA - Rasio rega marang bathi tumrap wutah|Nilai bisnis marang bathi operasional sadurunge panyusutan Verona Pharma Corp|VRNA - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi resik saben saham sajrone 12 wulan pungkasan Verona Pharma|VRNA - Bathi resik saben saham (EPS TTM)|Wutah bathi EPS kuartalan veronapharma.com|VRNA - Wutah bathi resik saben saham ing taun iki|Dinamika bathi saben saham sing diarepake ing taun ngarep Verona Pharma plc
- data total pendapatan lan volume dodolan:
Analisis umum perusahaan:VRNA veronapharma.com
During the launch phase of its first drug and the establishment of distribution networks for organic growth, Verona Pharma plc (VRNA) is exhibiting specific revenue dynamics. By analyzing the price-to-sales ratio, an investor determines the business value per unit of revenue, where a low multiple serves as a defensive buffer, while a high valuation on this chart signals inflated market expectations regarding future expansion.
Karo sapa Verona Pharma plc saingan
HLN (haleon.com) - Rasio kapitalisasi pasar marang pendapatan|Kenvue - Kapitalisasi marang pendapatan|Jyong Biotech Limited - Rasio rega marang pendapatan|Ligand Pharma - Multiplikator P/S|Rega marang dodolan Amneal Corp|Perrigo Company plc (PRGO) - Rasio rega marang pendapatan|alvotech.com - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Liquidia|Rega marang dodolan Galapagos N.V. GLPG|Rasio rega marang pendapatan ANI Pharma (ANIP)|Afrezza - Rasio kapitalisasi marang pendapatan|Multiplikator P/S AMPH (Amphastar Pharmaceuticals)|Multiplikator P/S pacira.com PCRX|SPRY: Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan TBPH (Theravance Biopharma Inc)|Aquestive Pharma (AQST) - Rasio rega marang pendapatan|Rasio rega marang dodolan SCPH (scPharmaceuticals)|TECX (Tectonic Therapeutic Inc.) - Multiplikator P/S|TNXP: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S SXTC|Multiplikator P/S eupraxiapharma.com (EPRX)|Rasio rega marang pendapatan BioHarvest BHST|Rasio kapitalisasi pasar marang pendapatan EXOZ|ORMP - Rasio rega marang pendapatan|Entera Bio Ltd. (ENTX) - Kapitalisasi marang pendapatan|HYFT: Multiplikator P/S|ABVC BioPharma Inc. (ABVC) - Multiplikator P/S|Kapitalisasi marang pendapatan CPIX|QNTM: Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan FibroGen, Inc. (FGEN)|TELO: Rasio rega marang dodolan|Rasio rega marang pendapatan Rani Therapeutics Holdings, Inc. RANI|Synergy CHC Corp. - Rasio rega marang pendapatan|Rallybio Corp. - Multiplikator P/S|Lexaria Bioscience (LEXX) - Kapitalisasi marang pendapatan|PULM (Pulmatrix, Inc.) - Kapitalisasi marang pendapatan|PTHL (Pheton Holdings) - Rasio rega marang pendapatan|Rasio rega marang pendapatan Aptorum Group Ltd|LYRA: Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Impact BioMedical (IBO)|tnfpharma.com - Rasio kapitalisasi marang pendapatan|Multiplikator P/S YCBD (cbdMD)|Multiplikator P/S painreform.com PRFX|CYTO - Rasio rega marang pendapatan|Rasio rega marang dodolan LIPO|OPTN: Multiplikator P/S|Pieris Pharma - Rasio kapitalisasi pasar marang pendapatan|PROC (Procaps Group S.A.) - Multiplikator P/S|Multiplikator P/S petrospharma.com|Rasio rega marang pendapatan Qilian International Holding (QLI)|SLRN (Acelyrin Inc.) - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan TFF Pharma TFFP
